Saturday, February 22, 2014 12:09:11 AM
Here is the flaw in all of the critiques of Gerald's financial acumen. He could have an MBA from Wharton with a dissertation in Biotech Financial Deals and it simply would not matter until the AMBS science reached a 'critical mass' consisting of successful clinical trials with potentially competitively advantaged products,
Substitute any of AMBS' current product pipeline where you see underlines below, and ask yourself honestly if any AMBS product currently belongs there.
And test my proposition with this question. If a deal for any of AMBS product were announced on Monday next, would it be because Gerald or his financial deals staff 'all-star' suddenly became competent in ways they formerly were not, or would it more likely be because newly persuasive scientific data became available?
I'm not saying that Gerald has not turned away low-ball offers, I simply don't know. I am suggesting that AMBS is not as scientifically strong, at this point, as are companies that AMBS is being unfavorably compared with in deal making.
The one below is so clearly an apples to oranges comparison with AMBS, product data wise, it begs the question of why it was even posted.
http://ih.advfn.com/p.php?pid=nmona&article=61169657
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM